Barcelona – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».
Archives de l’auteur : Marianne Duparc
OPTIONS X
Singapore – Oral Presentations and PostersAlexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ». Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present « Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human …
Influenza Vaccines for the World
Edinburgh – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled « OVX836 protects mice in lethal challenges with multiples strains of influenza A viruses ».
World Influenza Conference
Beijing – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present preclinical results of OVX836 as part of a poster entitled « OVX836 a multimerized nucleoprotein based vaccine candidate protects mice against lethal challenges of multiple strains of influenza A viruses ».
Universal Influenza Vaccines
Lausanne – Oral PresentationDr. Fergal Hill, Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled « OVX836, a multimerized nucleoprotein (NP) induces cellular responses against NP in various animal models challenges of multiple strains of influenza A viruses ».